I believe Tall Allen reported on the first one but the others may interest you also.
Some interesting Findings from ASTRO - Advanced Prostate...
Some interesting Findings from ASTRO


Here is an excerpt of Short-term ADT plus radiotherapy improves disease-free survival in higher-risk prostate cancer:
“Given the adverse effects of ADT, it is commonly underused in real-world settings, with men receiving considerably shorter durations of ADT than indicated,” Kishan and colleagues wrote.
In GETUG 14, Demogeot and colleagues randomized 376 patients with intermediate to high prostate cancer risk to either short-term ADT plus radiotherapy (n = 179) or lone radiotherapy (n = 191). Both treatment arms received an 80 Gy dose; ADT was monthly triptorelin and daily flutamide over 4 months, starting 2 months before irradiation.
The team sought a primary endpoint of disease-free survival, and secondary endpoints including overall survival, biochemical failure, metastasis failure, toxicity, and patient-reported quality of life.
Over a median follow-up period of 84 months, investigators observed a 5-year disease-free survival of 84% among the short-term ADT plus radiotherapy arm, versus 76% among the radiotherapy arm—indicating a 36% reduced risk (hazard ratio [HR], 0.64; 95% CI, 0.43 – 0.89; P = .02). The addition of short-term ADT was also associated with significantly reduced biochemical failure (HR, 0.45; P = .001) and metastasis failure (HR, 0.50; P = .09). However, overall survival was not significantly improved with the combination therapy versus radiotherapy (HR, 1.22; P = .54).
So they are saying 2 months of ADT before RT and another 2 months after RT. Much smaller window than the 18 to 36 months of ADT from earlier recommendations.
However they seem to compare 4 months of ADT plus 80 Gy of RT vs 80 Gy of RT alone. I don't see a comparison between 4 months of ADT plus 80 Gy of RT vs 18 months of ADT plus 80 Gy of RT.
Very small study. For localized PCa patients getting RT.